FDA approves J&J's analgesic tapentadol
This article was originally published in Scrip
Executive Summary
Johnson & Johnson has received US FDA approval for its analgesic tapentadol hydrochloride, an immediate-release oral tablet, for the relief of moderate-to-severe acute pain in the US, its first market.